Jagsonpal Pharmaceuticals Ltd

Jagsonpal Pharma Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Jagsonpal Pharmaceuticals Ltd

₹ 418 0.40%
29 Sep 3:09 p.m.
jagsonpal.com BSE: 507789 NSE : JAGSNPHARM
About

Jagsonpal Pharmaceuticals Ltd is primarily engaged in the manufacturing and trading of pharmaceutical products and APIs. It has operations in India and caters to both domestic and international markets.[1]

Key Points

Product Offerings
The company offers a range of pharmaceutical products under key therapeutic areas i.e. allergy management, immunity, cell protection, dentistry and ENT, women's healthcare, pregnancy care, and bone and joint care. [1]

Website BSE NSE
  • Market Cap ₹ 1,095 Cr.
  • Current Price ₹ 418
  • High / Low ₹ 515 / 280
  • Stock P/E 35.0
  • Book Value ₹ 60.6
  • Dividend Yield 1.19 %
  • ROCE 25.6 %
  • ROE 19.9 %
  • Face Value ₹ 5.00
Edit ratios

Pros

  • Company is almost debt free.
  • Company has delivered good profit growth of 35.2% CAGR over last 5 years
  • Company has been maintaining a healthy dividend payout of 40.0%
  • Company's working capital requirements have reduced from 46.6 days to 35.6 days

Cons

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln

Edit Columns
Loading peers table ...

Quarterly Results

Figures in Rs. Crores

Jun 2020 Sep 2020 Dec 2020 Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023
31.65 56.35 57.10 42.84 54.05 59.49 54.47 51.23 60.60 60.53 60.14 55.45 60.15
29.00 51.51 50.61 37.72 44.77 50.09 48.85 50.45 53.42 47.62 51.50 50.01 51.52
Operating Profit 2.65 4.84 6.49 5.12 9.28 9.40 5.62 0.78 7.18 12.91 8.64 5.44 8.63
OPM % 8.37% 8.59% 11.37% 11.95% 17.17% 15.80% 10.32% 1.52% 11.85% 21.33% 14.37% 9.81% 14.35%
0.78 0.41 0.53 2.66 0.82 0.28 1.95 0.37 -3.15 1.12 1.74 2.56 2.00
Interest 0.13 0.12 0.14 0.13 0.11 0.06 0.06 0.06 0.01 0.03 0.18 0.20 0.15
Depreciation 0.27 0.27 0.27 0.26 0.28 0.23 0.37 0.65 0.19 0.20 0.33 0.48 0.39
Profit before tax 3.03 4.86 6.61 7.39 9.71 9.39 7.14 0.44 3.83 13.80 9.87 7.32 10.09
Tax % 16.83% 17.49% 17.85% 30.85% 29.45% 30.24% 24.23% 31.82% 23.50% 24.49% 21.07% 23.50% 25.87%
2.52 4.01 5.43 5.10 6.85 6.56 5.41 0.31 2.92 10.41 7.78 5.60 7.48
EPS in Rs 0.96 1.53 2.07 1.95 2.61 2.50 2.07 0.12 1.11 3.97 2.97 2.14 2.86
Raw PDF

Profit & Loss

Figures in Rs. Crores

Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 TTM
177 166 144 138 143 144 127 167 159 188 218 237 236
160 156 133 129 132 138 138 157 150 169 192 202 201
Operating Profit 17 10 11 9 12 6 -11 9 9 19 26 35 36
OPM % 9% 6% 7% 6% 8% 4% -9% 6% 5% 10% 12% 15% 15%
0 0 0 0 1 13 0 1 3 4 3 2 7
Interest 4 5 5 4 5 3 1 1 1 1 0 0 1
Depreciation 3 3 3 3 3 2 0 1 1 1 2 1 1
Profit before tax 10 3 3 2 4 14 -12 9 9 22 27 35 41
Tax % 26% 28% 16% 30% 20% 18% 1% 20% 16% 22% 29% 23%
7 2 2 1 3 12 -12 7 8 17 19 27 31
EPS in Rs 2.85 0.70 0.81 0.45 1.24 4.53 -4.41 2.76 3.00 6.51 7.20 10.20 11.94
Dividend Payout % 18% 72% 62% 22% 8% 2% -2% 9% 17% 15% 56% 49%
Compounded Sales Growth
10 Years: 4%
5 Years: 13%
3 Years: 14%
TTM: 5%
Compounded Profit Growth
10 Years: 32%
5 Years: 35%
3 Years: 54%
TTM: 83%
Stock Price CAGR
10 Years: 47%
5 Years: 74%
3 Years: 123%
1 Year: 14%
Return on Equity
10 Years: 7%
5 Years: 13%
3 Years: 17%
Last Year: 20%

Balance Sheet

Figures in Rs. Crores

Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
13 13 13 13 13 13 13 13 13 13 13 13
Reserves 85 85 85 82 85 97 85 91 98 109 120 146
35 33 36 39 38 8 8 4 6 7 0 6
23 21 22 19 22 25 23 28 31 35 31 30
Total Liabilities 156 153 156 154 159 143 130 136 149 164 164 195
59 58 56 52 52 22 21 22 24 26 23 24
CWIP 1 2 2 0 0 0 3 4 2 0 0 0
Investments 0 0 0 0 0 0 0 0 11 15 51 1
96 92 98 102 108 121 105 110 111 123 91 170
Total Assets 156 153 156 154 159 143 130 136 149 164 164 195

Cash Flows

Figures in Rs. Crores

Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
7 12 8 4 9 -3 -2 31 12 28 7 47
-5 -3 -1 -0 -2 41 -3 -1 -11 -2 -26 -58
0 -8 -4 -1 -6 -34 -1 -6 -2 -7 -18 -0
Net Cash Flow 3 0 2 2 1 5 -6 24 -1 19 -36 -11

Ratios

Figures in Rs. Crores

Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Debtor Days 87 93 115 119 106 100 73 45 49 25 26 32
Inventory Days 152 127 173 176 246 295 307 164 191 134 122 81
Days Payable 35 28 29 42 60 56 54 59 76 82 76 64
Cash Conversion Cycle 204 192 259 252 292 339 325 150 164 77 72 49
Working Capital Days 129 130 155 171 169 174 173 76 64 45 59 36
ROCE % 11% 6% 6% 5% 7% 3% -10% 9% 9% 18% 20% 26%

Shareholding Pattern

Numbers in percentages

Sep 2020Dec 2020Mar 2021Jun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023
70.34% 70.34% 70.34% 70.34% 70.34% 70.34% 68.71% 68.71% 68.72% 68.72% 68.72% 68.72%
0.00% 0.00% 0.00% 0.00% 0.11% 0.20% 0.00% 0.00% 0.13% 0.11% 0.10% 0.37%
0.00% 0.00% 0.00% 0.00% 0.01% 0.00% 0.67% 0.68% 0.28% 0.77% 0.82% 0.82%
29.66% 29.66% 29.65% 29.65% 29.54% 29.46% 30.61% 30.61% 30.85% 30.40% 30.34% 30.07%
No. of Shareholders 10,33612,13112,54614,65514,35320,03117,10016,19414,95214,53514,08413,782

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

Credit ratings

Concalls

  • May 2023
    Transcript
    Notes
    PPT
  • Feb 2023
    Transcript
    Notes
    PPT
  • Feb 2022
    Transcript
    Notes
    PPT